I disagree on the point that sales are required. Janssen (Johnson & Johnson) obviously have a front seat with PIQ via their collaborative research. They have a complimentary drug and (effectively) unlimited financial capacity.
If PIQ validates the product it seems a no-brainer that Janssen will strike some sort or deal/arrangement that will be highly lucrative. At that point, if it occurs, PIQ will re-rate by an order of magnitude. imho.
PIQ Price at posting:
$1.34 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)